Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels

Journal of Cellular Physiology

Volumn 217, Issue 1, 2008, Pages 13-22

  Ueno, Shinji ^a   Pease, Mary Ellen ^a   Bonnet Wersinger, Delphine M ^a   Masuda, Tomohiro ^a   Vinores, Stanley A ^a   Licht, Tamar ^b   Zack, Donald J ^a   Quigley, Harry ^a   Keshet, Eli ^b   Campochiaro, Peter A ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; FC RECEPTOR; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL PERMEABILITY; BRUCH MEMBRANE; CHOROID; CONTROLLED STUDY; ELECTRORETINOGRAM; FENESTRATION; MEMBRANE RUPTURE; MOUSE; NERVE CELL; NERVE CELL LESION; NERVE FIBER; NONHUMAN; OPTIC NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; RETINA; RETINA BLOOD VESSEL; RETINA INJURY; RETINA NERVE CELL; SUBRETINAL NEOVASCULARIZATION; TRANSGENIC MOUSE; ULTRASTRUCTURE ANALYSIS AND ELECTRON MICROSCOPY; ANGIOGENESIS; ANIMAL; APOPTOSIS; DRUG ANTAGONISM; METABOLISM; NICK END LABELING; RETINA GANGLION CELL; RETINA NEOVASCULARIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

MUS; MUS MUSCULUS;

ANIMALS; APOPTOSIS; CHOROIDAL NEOVASCULARIZATION; IN SITU NICK-END LABELING; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; NEOVASCULARIZATION, PHYSIOLOGIC; RETINAL GANGLION CELLS; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 49649103814     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21445     Document Type: Article

References (46)

1. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. 1995. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med 1:1024-1028.
2. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A. 2006. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695-1705.
3. Baffert F, Le T, Sennino B, Thruston F, Kuo C, Hu-Lowe D, McDonald DM. 2006. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 290:H547-H559.
4. Bakri SJ, Donaldson MJ, Link TP. 2006. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye 20:1474-1475.
5. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, Group AS. 2006. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Eng J Med 355:1432-1444.
6. Campochiaro PA. 2006. Molecular targets for retinal vascular diseases. J Cell Physiol 210:575-581.
7. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon SD, Sung JU, Hadi Y, Janjua KA, Jawed N, Choy DF, Arron JR. 2008. Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator. Mol Ther 16:791-799.
8. Chang MA, Horner JW, Conklin BR, DePinho RA, Bok D, Zack DJ. 2000. Tetracycline-inducible system for photo receptor-specific gene expression. Invest Ophthalmol Vis Sci 41:4281-4287.
9. Costa RA, Jorge LA, Calucci D, Melo LAJ, Cardillo JA, Scott IU. 2007. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions IBeVO Study. Retina 27:141-149.
10. Derevjanik NL, Vinores SA, Xiao W-H, Mori K, Turon T, Hudish T, Dong S, Campochiaro PA. 2002. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci 43:2462-2467.
11. Friedlander SM, Welch RM. 2006. Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection. Arch Ophthalmol 124:1365.
12. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Yung S, Chimenti S, Landsman L, Abramaovitch R, Keshet E. 2006. VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells. Cell 124:175-1189.
13. Holash J, Davis S, Papadoupoulos N, Croll SD, Ho L, Russell M, Boland P, Ledich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. 2002. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393-11398.
14. Iriyama A, Chen Y-N, Tamaki Y, Yanagi Y. 2007. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 91:1230-1233.
15. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF. 2006. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina 26:279-284.
16. Ivanov D, Dvoriantchikova G, Nathanson L, McKinnon SJ, Shestopalov VI. 2006. Microarray analysis of gene expression in adult retinal ganglion cells. FEBS Lett 580:331-335.
17. Jin KL, Mao XO, Greenberg DA. 2000. Vascular endothelial growth factor: Direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 97:10242-10247.
18. Kamba T, Tam BYY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM. 2005. VEGF-dependent plasticity of fenestrated capillaries in the normal adulat microvasculature. Am J Physiol Heart Circ Physiol 290:H560-H576.
19. Keshet E. 2008. Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci USA 105:282-287.
20. Kilic U, Kilic E, Jarve A, Guo Z, Spudich A, Bieber K, Barzena U, Bassetti CL, Marti HH, Hermann DM. 2006. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neuosci 26:12439-12446.
21. Kim CY, Kuehn MH, Clark AF, Kwon YH. 2006. Gene expression profile of the adult human retinal ganglion cell layer. Mol Vis 12:1640-1648.
22. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, Bujard H. 1996. Doxycycline-mediated quantitative and tissue specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA 93:10933-10938.
23. Komeima K, Rogers BS, Campochiaro PA. 2007. Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol 213:809-815.
24. Kwak N, Okamoto N, Wood JM, Campochiaro PA. 2000. VEGF is an important stimulator in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41:3158-3164.
25. Mason JO 3rd, Nixon PA, White MF. 2006. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 142:685-688.
26. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA. 2006. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142:961-969.
27. Nguyen QD, Shah SM, Hafiz G, Do DV, Haller JA, Pili R, Zimmer-Galler I, Janjua K, Symons RCA, Campochiaro PA. 2008. Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. Am J Ophthalmol 145:257-266.
28. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT. 2007. Vascular endothelial growth factor-A is a survivial factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171:53-67.
29. Ohno-Matsui K, Hirose A, Yamamoto S, SaikiaJ, Okamoto N, Gehlbach P, Duh EJ, Hackett SF, Chang M, Bok D, Zack DJ, Campochiaro PA. 2002. Inducible expression of vascular endothelial growth factor in photoreceptors of adult mice causes severe proliferative retinopathy and retinal detachment. Am J Pathol 160:711-719.
30. Okoye G, Zimmer J, Sung JPG, Deering T, Nambu N, Hackett SF, Melia M, Esumi N, Zack DJ, Campochiaro PA. 2003. Increased expression of BDNF preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage. J Neuosci 23:4164-4172.
31. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Dorpe JV, Hellings P, Gorselink M, Heymans S, Theilmeier G, Dewerchin M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujisawa H, Drost MR, Sciot R, Bruyninckx F, Hicklin DJ, Ince C, Gressens P, Lupu F, Plate KH, Robberecht W, Herbert J-M, Collen D, Carmeliet P. 2001. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28:131-138.
32. Oshima Y, Oshima S, Nambu H, Kachi S, Takahashi K, Umeda N, Shen J, Dong A, Apte RS, Duh E, Hackett SF, Okoye G, Ishibashi K, Handa J, Melia M, Wiegand S, Yancopoulos G, Zack DJ, Campochiaro PA. 2005. Different effects of angiopoietin 2 in different vascular beds in the eye; new vessels are most sensitive. FASEB J 19:963-965.
33. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM. 2007. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601-606.
34. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Group TBS, Schraermeyer U. 2007. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143:995-1002.
35. Pournaras CJ, Tsacopoulos M, Strommer K, Gilodi N, Leuenberger PM. 1990. Scatter photocoagulation restores tissue hypoxia in experimental vasoproliferative microangiopathy in miniature pigs. Ophthalmology 97:1329-1333.
36. Rabena MD, Pieramici DJ, Castellarin AA, Nair MA, Avery RL. 2007. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419-425.
37. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS. 2006. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med 355:1419-1431.
38. R1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:241-248.
39. Saishin Y, Saishin Y, Takahashi K, Melia M, Vinores SA, Campochiaro PA. 2003b. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier, J Cell Physiol 195:210-219.
40. Seo M-S, Kwak N, Ozaki H, Yamada H, Okamoto N, Fabbro D, Hofmann F, Wood JM, Campochiaro PA. 1999. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 154:1743-1753.
41. Stahl A, Agostini H, Lutz HL, Feltgen N. 2007. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefe's Arch Clin Exp Ophthalmol 245:1429-1436.
42. Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano MP, Appelmans S, Oh H, Van Damme P, Rutten B, Man WY, De Mol M, Wyns S, Manka D, Vermeulen K, Van Den Bosch L, Mertens N, Scmitz C, Robberecht W, Conway EM, Collen D, Moons L, Carmeliet P. 2005. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8:85-92.
43. Tobe T, Ortega S, Luna JD, Ozaki H, Okamoto N, Derevjanik NL, Vinores SA, Basilico C, Campochiaro PA. 1998. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 153:1641-1646.
44. Verbeke G, Molenberghs G. 2000. Linear mixed models for longitudinal data. New York: Springer-Verlag, Inc.
45. Wang Y, Mao XO, Xie L, Banwait S, Marti HH, Greenberg DA, Jin K. 2007. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neuosci 27:304-307.
46. Yu Z, Redfern CS, Fishman GI. 1996. Conditional transgene expression in the heart. Circ Res 79:691-697.